Abiomed

Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.

PreCardia is a medical device company focused on developing inpatient partially implantable devices for the treatment of acute decompensated heart failure (ADHF). Its innovative devices utilize intermittent superior vena cava occlusion to manage venous return to the heart, aiming to meet essential clinical hemodynamic targets associated with ADHF. By addressing the specific needs of patients suffering from this condition, PreCardia seeks to enhance treatment outcomes and improve patient care in a hospital setting.

Breethe, Inc. is a medical device company founded in 2014 and headquartered in Baltimore, Maryland. It specializes in the development and commercialization of wearable artificial lungs, specifically the OXY-1 System, which provides external respiratory assistance to patients experiencing acute respiratory failure and chronic lung issues. This portable device facilitates gas exchange by removing carbon dioxide and adding oxygen to the blood, mimicking the function of a healthy lung. By eliminating the need for cumbersome oxygen tanks, the OXY-1 System allows patients to maintain mobility while receiving essential ECMO therapy. Breethe aims to improve treatment outcomes for individuals suffering from severe lung conditions through innovative technology.

Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Protembis GmbH, established in 2017 and based in Aachen, Germany, specializes in the development of innovative surgical equipment, particularly focusing on minimally invasive medical devices. The company's flagship product, the ProtEmbo System, is an intra-aortic filter designed to mitigate the risk of cerebrovascular events during transcatheter aortic valve replacement (TAVR) procedures. This device effectively deflects embolic material generated during these cardiovascular interventions away from the cerebral circulation, thereby reducing the likelihood of brain injury. By enhancing the safety of TAVR, Protembis aims to improve patient outcomes, particularly as this procedure becomes more common among younger and lower-risk individuals. Through its advancements, Protembis is committed to increasing the quality of life for patients while also addressing the broader healthcare costs associated with complications arising from surgical interventions.

RenalGuard Solutions develops and markets medical devices for cardiac and vascular care that rapidly remove contrast dyes, which can be toxic to the kidneys, to reduce the risk of contrast-induced nephropathy in at-risk patients undergoing imaging procedures. Its RenalGuard System combines a console and a single-use set to manage fluids during procedures, and RenalGuard Therapy aims to mitigate contrast-related kidney injury. The company distributes its products through a network of distributors in the United States and internationally. It was founded in 1982 and is headquartered in Milford, Massachusetts. The technology has EU approval for general fluid balancing, and European studies have demonstrated effectiveness in preventing CIN, with a pivotal trial in the United States progressing for FDA review.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, established in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure. Its flagship product, the Reprieve technology, offers a solution for clinicians to precisely control the fluid volume in patients suffering from acute decompensated heart failure (ADHF). This ability to manage fluid levels is essential for improving cardiac care and assisting in the decongestion process for these patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

ALung Technologies, Inc., established in 1997 and based in Pittsburgh, Pennsylvania, specializes in developing and manufacturing medical devices for treating acute respiratory failure. The company's primary product is the Hemolung Respiratory Assist System, a dialysis-like device that removes carbon dioxide and delivers oxygen directly to the blood, allowing patients' lungs to rest and heal while avoiding intubation and facilitating protective ventilation.

ECP Entwicklungsgesellschaft is a a medical device company and is developing a product that is a percutaneous, expandable catheter pump which increases blood circulation from the heart with an external drive shaft.

Impella CardioSystems AG, located in Aachen, Germany, specializes in the development, manufacturing, and marketing of minimally invasive cardiovascular support systems designed for various cardiology and coronary surgery applications. The company produces intracorporeal micro blood pumps, which are utilized to support patients undergoing these medical procedures. With a robust portfolio of over 30 European and international patents protecting its innovative technology, Impella employs a team of 50 individuals. For the past two years, the company has collaborated with Accelerated Technologies, Inc., a medical device accelerator based in Hackensack, New Jersey, to enhance its growth and development in the medical device sector.